Plain-English translation of NCT07234162 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to see if it can help adults whose T-cell lymphoma has come back or stopped responding to previous treatments. You would be randomly assigned to either receive or a standard treatment chosen by your doctor. The study will compare how well the medication works and how safe it is.
T-cell lymphoma is a serious blood cancer, and many patients find that standard treatments stop working or their cancer returns. This trial exists to see whether this new medication could offer a better option for patients in this difficult situation.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either or a standard treatment chosen by your doctor. The study is open-label, meaning you and your doctor will know which treatment you're receiving. You would visit the clinic regularly for checkups, blood tests, and scans to see how the treatment is working. The trial involves 218 participants across multiple countries and is still enrolling patients.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China